Citadel Advisors
BCYC

Citadel Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Citadel Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$66.4K Sell
14,300
-14,000
-49% -$80K ﹤0.01% 12282
2025
Q4 		$200K Buy
+28,300
New +$209K ﹤0.01% 11045
2025
Q3 		– Sell
-17,700
Closed -$123K – 12763
2025
Q2 		$123K Buy
17,700
+10,100
+133% +$80.5K ﹤0.01% 11141
2025
Q1 		$64.5K Buy
7,600
+3,500
+85% +$41.2K ﹤0.01% 12021
2024
Q4 		$57.4K Sell
4,100
-7,500
-65% -$161K ﹤0.01% 12237
2024
Q3 		$263K Buy
11,600
+8,200
+241% +$189K ﹤0.01% 9586
2024
Q2 		$68.8K Sell
3,400
-3,000
-47% -$67.8K ﹤0.01% 11394
2024
Q1 		$159K Sell
6,400
-5,800
-48% -$123K ﹤0.01% 10671
2023
Q4 		$221K Buy
12,200
+8,000
+190% +$132K ﹤0.01% 9749
2023
Q3 		$84.4K Buy
4,200
+1,300
+45% +$29.7K ﹤0.01% 11100
2023
Q2 		$74K Sell
2,900
-1,200
-29% -$27.9K ﹤0.01% 11328
2023
Q1 		$87.2K Sell
4,100
-2,200
-35% -$55.2K ﹤0.01% 11448
2022
Q4 		$186K Buy
+6,300
New +$169K ﹤0.01% 10252
2022
Q3 		– Sell
-81,200
Closed -$1.36M – 12606
2022
Q2 		$1.36M Buy
81,200
+64,000
+372% +$1.35M ﹤0.01% 6334
2022
Q1 		$755K Buy
17,200
+3,800
+28% +$177K ﹤0.01% 8379
2021
Q4 		$816K Buy
13,400
+7,600
+131% +$419K ﹤0.01% 8442
2021
Q3 		$241K Buy
+5,800
New +$203K ﹤0.01% 11557

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's BCYC Position: Q1 2026 in Review

Citadel Advisors increased its Bicycle Therapeutics (BCYC) stake by 39% in Q1 2026, buying an estimated $604K and bringing the position to 377,085 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #6374.

Citadel Advisors first reported a position in BCYC in Q4 2020 and has held it in 19 quarters since. The position peaked at $5.32M in Q4 2023. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Citadel Advisors held 377,085 shares of Bicycle Therapeutics worth $1.75M as of Q1 2026.
  • Citadel Advisors bought 105,702 Bicycle Therapeutics shares in Q1 2026, an estimated $604K.
  • Bicycle Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6374 holding.
  • Citadel Advisors first reported a position in Bicycle Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Citadel Advisors's Bicycle Therapeutics position peaked at $5.32M in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.